Mitoxantron (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mitoxantron" in Czech language version.

refsWebsite

Global rank Czech rank

2^nd place

4^th place

4^th place

8^th place

610^th place

203^rd place

low place

6,557^th place

485^th place

155^th place

5^th place

3^rd place

doi.org

PARKER, Catriona; WATERS, Rachel; LEIGHTON, Carly. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. The Lancet. 2010-12, roč. 376, čís. 9757, s. 2009–2017. Dostupné online [cit. 2023-11-30]. doi:10.1016/S0140-6736(10)62002-8. PMID 21131038. (anglicky)
Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clinical Therapeutics. April 2006, s. 461–474. doi:10.1016/j.clinthera.2006.04.013. PMID 16750460.
WU, Chyuan-Chuan; LI, Yi-Ching; WANG, Ying-Ren. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Research. 2013-12, roč. 41, čís. 22, s. 10630–10640. Dostupné online [cit. 2023-11-30]. ISSN 1362-4962. doi:10.1093/nar/gkt828. PMID 24038465. (anglicky)

PARKER, Catriona; WATERS, Rachel; LEIGHTON, Carly. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. The Lancet. 2010-12, roč. 376, čís. 9757, s. 2009–2017. Dostupné online [cit. 2023-11-30]. doi:10.1016/S0140-6736(10)62002-8. PMID 21131038. (anglicky)

PARKER, Catriona; WATERS, Rachel; LEIGHTON, Carly. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. The Lancet. 2010-12, roč. 376, čís. 9757, s. 2009–2017. Dostupné online [cit. 2023-11-30]. doi:10.1016/S0140-6736(10)62002-8. PMID 21131038. (anglicky)
Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clinical Therapeutics. April 2006, s. 461–474. doi:10.1016/j.clinthera.2006.04.013. PMID 16750460.
WU, Chyuan-Chuan; LI, Yi-Ching; WANG, Ying-Ren. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Research. 2013-12, roč. 41, čís. 22, s. 10630–10640. Dostupné online [cit. 2023-11-30]. ISSN 1362-4962. doi:10.1093/nar/gkt828. PMID 24038465. (anglicky)

WU, Chyuan-Chuan; LI, Yi-Ching; WANG, Ying-Ren. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Research. 2013-12, roč. 41, čís. 22, s. 10630–10640. Dostupné online [cit. 2023-11-30]. ISSN 1362-4962. doi:10.1093/nar/gkt828. PMID 24038465. (anglicky)

Mitoxantron - modrý zázrak ze Synthesie pomáhá proti rakovině - Synthesia. www.synthesia.eu [online]. [cit. 2023-11-30]. Dostupné online.

WU, Chyuan-Chuan; LI, Yi-Ching; WANG, Ying-Ren. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Research. 2013-12, roč. 41, čís. 22, s. 10630–10640. Dostupné online [cit. 2023-11-30]. ISSN 1362-4962. doi:10.1093/nar/gkt828. PMID 24038465. (anglicky)